Denali Therapeutics Inc (DNLI) Stock
Key stats
- Market cap
- $3.16B
- Price / Earnings ratio
- -10.1x
- EPS (TTM)
- -$1.73
- Volume
- Loading
- 52-week high
- $27.30
- 52-week low
- $15.18
Source: third-party data provider, as of November 13, 2026
Compare with DNLI
Recent news

Denali Therapeutics Q3 Earnings Call Highlights
Denali Therapeutics Q3 Earnings Call Highlights
DNLI

Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates
DNLI

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
DNLI

DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
DNLI
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 50.92
- MACD 12/26/9
- 0.05
- EMA 9 of MACD
- -0.14
- MACD histogram
- 0.19
- SMA 50
- $19.93
- Price below SMA 50
- EMA 50
- $20.17
- Price below EMA 50
- SMA 200
- $21.25
- Price below SMA 200
- EMA 200
- $20.39
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.78 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Denali Therapeutics Q3 Earnings Call Highlights
Denali Therapeutics Q3 Earnings Call Highlights
DNLI

Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates
DNLI

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
DNLI

DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
DNLI

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
DNLI

Denali Therapeutics Q2 Earnings Call Highlights
Denali Therapeutics Q2 Earnings Call Highlights
DNLI

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
DNLI

Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
DNLI

DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
DNLI

Denali to Sell Priority Review Voucher for $195M Cash Boost
Denali to Sell Priority Review Voucher for $195M Cash Boost
DNLI
News tone: automated (AI) classification of the article's content, not a price prediction.
About Denali Therapeutics Inc
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Ryan J. Watts Ph.D. | Co-Founder, President, CEO & Director | 1976 |
| Dr. Alexander O. Schuth M.D., Ph.D. | Co-Founder, CFO, COO & Secretary | 1973 |
| Dr. Dana Andersen | Chief Technical and Manufacturing Officer | — |
| Mr. Joe Lewcock Ph.D. | Chief Scientific Officer | — |
| Mr. Chris Walsh J.D. | General Counsel | — |
| Ms. Cindy Dunkle | Chief People Officer | — |
| Ms. Katie Peng M.B.A. | Chief Commercial Officer | 1971 |
| Mr. Peter Chin M.D. | Acting Chief Medical Officer & Head of Development | 1968 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 50.92
- MACD 12/26/9
- 0.05
- EMA 9 of MACD
- -0.14
- MACD histogram
- 0.19
- SMA 50
- $19.93
- Price below SMA 50
- EMA 50
- $20.17
- Price below EMA 50
- SMA 200
- $21.25
- Price below SMA 200
- EMA 200
- $20.39
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $24.00
- Average
- $35.00
- High
- $42.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -7.7 | +0.4 | ||||||||||
| 2022 | -27.6 | -7.9 | +0.2 | -32.0 | -3.4 | +23.2 | +8.9 | -15.6 | +9.7 | -7.6 | +10.2 | -10.9 |
| 2023 | +9.6 | -12.1 | -15.6 | +6.3 | +17.1 | -4.6 | -4.2 | -18.5 | -11.5 | -4.9 | -2.7 | +13.1 |
| 2024 | -25.2 | +20.7 | -1.6 | -24.9 | +14.9 | +13.9 | +10.7 | +4.8 | +16.0 | -9.5 | -7.6 | -20.5 |
| 2025 | +11.8 | -24.2 | -10.5 | +35.5 | -17.6 | +0.2 | -0.9 | +13.6 | -6.0 | +9.2 | +26.8 | -9.1 |
| 2026 | +33.6 | -6.9 | -8.6 | -4.9 | +15.0 | +26.0 | -11.4 | +2.6 | -11.2 | -7.7 | +4.6 |



